Savara (NASDAQ:SVRA - Get Free Report)'s stock had its "market outperform" rating reaffirmed by investment analysts at JMP Securities in a report issued on Thursday, Benzinga reports. They currently have a $8.00 price target on the stock. JMP Securities' target price suggests a potential upside of 67.01% from the stock's previous close.
Separately, Piper Sandler lifted their price target on Savara from $7.00 to $16.00 and gave the company an "overweight" rating in a research note on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $8.20.
Check Out Our Latest Stock Analysis on SVRA
Savara Trading Down 3.4 %
Savara stock traded down $0.17 during trading hours on Thursday, reaching $4.79. 1,204,771 shares of the company's stock were exchanged, compared to its average volume of 851,426. The company has a quick ratio of 15.66, a current ratio of 15.66 and a debt-to-equity ratio of 0.19. The firm's 50 day simple moving average is $4.97 and its 200 day simple moving average is $4.39. The firm has a market capitalization of $661.74 million, a PE ratio of -14.88 and a beta of 0.77. Savara has a twelve month low of $1.76 and a twelve month high of $5.70.
Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Research analysts predict that Savara will post -0.38 earnings per share for the current year.
Hedge Funds Weigh In On Savara
Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada bought a new stake in shares of Savara in the 2nd quarter worth approximately $25,000. AJOVista LLC bought a new stake in shares of Savara in the 4th quarter worth approximately $40,000. Alliancebernstein L.P. bought a new stake in shares of Savara in the 2nd quarter worth approximately $38,000. XTX Topco Ltd bought a new stake in shares of Savara in the 2nd quarter worth approximately $40,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Savara in the 3rd quarter worth approximately $48,000. Institutional investors own 87.93% of the company's stock.
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
